Resources

As clinical trials evolve, one thing is certain: representativeness is no longer a nice-to-have; it’s a non-negotiable. The data are clear. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, 84% reported ramping up efforts to improve representativeness and accessibility in clinical research over the past few years.

Reflecting on the discussions from this year’s International Society for Pharmacoepidemiology (ISPE) Annual Meeting and looking ahead to the future of the field, I’m struck by the steady but significant evolution pharmacoepidemiology is undergoing driven in large part by innovations in real-world data (RWD).

Many clinical data networks often focus on a single use-case or disease. By contrast, the TriNetX Dataworks-USA Network contains real-world clinical information that can be applied to multiple research questions and use cases.

To characterize the use of and factors associated with GLP-1 initiation among US adults undergoing bariatric surgery.

Sanofi UK, a leading pharmaceutical company, sought an innovative solution to address challenges in clinical trial recruitment and feasibility.

There has been a proliferation of large-scale electronic health record (EHR) data platforms that pool across multiple healthcare organizations

Discover how partnering with TriNetX will enable you to advance rare disease research.

In just a few years, real-world data (RWD) has evolved from an industry buzzword to a core driver of progress in drug development. What used to be experimental is now operational and increasingly essential. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, more than three-quarters said their organizations are already applying RWD across some part of the drug development lifecycle. We’re clearly well beyond the pilot phase.

Pediatric obstructive sleep apnea (OSA) affects an estimated 1–3 % of children, corresponding to over 40 million cases globally.

Analysis reveals strategic opportunities for pharmaceutical leaders to close treatment gaps and accelerate breakthroughs in underserved rare disease communities.

TriNetX is compliant with the Health Insurance Portability and Accountability Act (HIPAA), the US federal law which protects the privacy and security of healthcare data. TriNetX is certified to the ISO 27001:2022 standard and maintains an Information Security Management System

Clostridioides difficile infection (CDI) is a major cause of infectious diarrhea in the inpatient and community setting